VRTX — Vertex Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $112.92bn
- $105.68bn
- $12.00bn
Brief: Vertex Announces Key Advancements Across Kidney Portfolio
Brief: Vertex Scientists Awarded The 2025 Lasker~Debakey Clinical Medical Research Award
WHO adds GLP-1 drugs for diabetes, others to essential medicines list
Brief: Enlaza Therapeutics Strategic Collaboration With Vertex Pharmaceuticals To Develop War-Lock Drug Conjugates And T-Cell Engagers
US stocks weekly: Reheat
US stocks weekly: Reheat
Live Markets: Weak data, tariff worries sour Wall Street's mood
U.S. STOCKS ON THE MOVE-Axon, Cummins, Pfizer
U.S. STOCKS ON THE MOVE-Axon, Cummins, Pfizer
Vertex falls after pain drug setback
U.S. STOCKS ON THE MOVE-Caterpillar, Pfizer, Zebra Technologies
U.S. STOCKS ON THE MOVE-Caterpillar, Pfizer, Zebra Technologies
Vertex falls after pain drug setback
Vertex tops estimates on cystic fibrosis treatment strength, new products
Vertex Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Vertex Pharmaceuticals slumps as experimental non-opioid painkiller fails mid-stage trial
Vertex to stop developing new painkiller as solo treatment after mid-stage study setback (updated)
Vertex's experimental pain drug fails main goal in mid-stage study
Brief: Vertex Announces Marketing Authorization In Canada For Alyftrek